Clinical Trials | December 18, 2025
Astellas & Pfizer report breakthrough Phase 3 results in muscle-invasive bladder cancer
The combination also outperformed chemotherapy on another important secondary endpoint
The combination also outperformed chemotherapy on another important secondary endpoint
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
Subscribe To Our Newsletter & Stay Updated
